TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Twist Bioscience Corp (TWST) is not a strong buy at the moment for a beginner, long-term investor. While the company shows potential for growth in the AI-driven drug discovery market and has received positive analyst ratings with raised price targets, the current technical indicators, financial performance, and trading sentiment do not support an immediate buy decision. The stock is experiencing a downward trend, and hedge funds are significantly selling, which could indicate short-term weakness. A 'hold' position is recommended until more favorable entry points or stronger signals emerge.
The technical indicators suggest a bearish trend. The MACD is negatively expanding below 0 (-0.711), RSI is neutral at 40.797, and moving averages are converging, indicating indecision. The stock is trading near its pivot level of 47.128, with support at 44.137 and resistance at 50.119. The stock has a 40% chance of declining further in the short term.
Positive analyst ratings and raised price targets driven by AI-driven drug discovery and NGS normalization. Revenue growth of 16.89% YoY in Q1 2026 and improved gross margin (52.05, up 7.79% YoY) indicate operational improvements.
Significant hedge fund selling (634.68% increase in selling over the last quarter). Net income dropped by -3.44% YoY, and EPS declined by -5.66% YoY. No recent news or congress trading data to support a bullish sentiment. The stock is currently down -4.09% in regular market trading and -5.47% in pre-market trading.
In Q1 2026, revenue increased by 16.89% YoY to $103.7M, and gross margin improved to 52.05 (up 7.79% YoY). However, net income dropped to -$30.5M (-3.44% YoY), and EPS declined to -0.5 (-5.66% YoY), indicating ongoing profitability challenges.
Analysts are optimistic, with multiple firms raising price targets to $50-$52 and maintaining Outperform or Buy ratings. The company is seen as well-positioned for growth in AI-driven drug discovery and diagnostics tools, with solid momentum into FY26.
